Servier
AmoyDx, Servier Partner to Develop CDx for Diffuse Glioma in China
The companies will develop a test to detect isocitrate dehydrogenase 1 and 2 gene mutations for use with Servier's investigational drug vorasidenib.
Abbott PCR Test Gets FDA Approval as CDx for Servier's Tibsovo for Rare Blood Cancer
The drug and test were approved for patients with relapsed or refractory myelodysplastic syndromes.
Servier, Qiagen to Develop PCR-Based Companion Diagnostic to Identify IDH1-Mutant Leukemia
Qiagen will develop a real-time PCR-based in vitro diagnostic to identify patients eligible for Servier's Tibsovo and investigational IDH1-targeted agents.
Servier, Celsius Therapeutics Partner to Identify Colorectal Cancer Drug Targets
Servier will have an exclusive option to research, develop, and commercialize products for up to three of the targets identified by Celsius.
Saga, Servier Sign Liquid Biopsy Services Deal
Saga has developed a digital PCR-based technology that it says can detect circulating tumor DNA with a mutational allele frequency of 0.001 percent.
Nov 27, 2017
Jul 3, 2014
May 23, 2013
Mar 13, 2013
France Funds $17M Cancer Profiling, Biomarker Effort
Oct 21, 2011
Oct 20, 2011